Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cisplatin + gemcitabine + itraconazole
- Development stage
- Phase 2
- Lead developer
- Sidney Kimmel Comprehensive Cancer Center
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Cisplatin + gemcitabine + itraconazole is an investigational combination chemotherapy regimen evaluated for the treatment of metastatic squamous non-small cell lung cancer (NSCLC). This regimen combines two standard cytotoxic agents—cisplatin, a platinum-based DNA crosslinking agent, and gemcitabine, a nucleoside analog—with SUBA™-itraconazole. While traditionally used as an antifungal, itraconazole is repurposed here for its antiangiogenic properties, specifically its ability to inhibit VEGF- and bFGF-mediated pathways, thereby suppressing endothelial cell proliferation and tube formation. The SUBA™ (supersaturated bioavailability) formulation of itraconazole is used to enhance oral absorption. A Phase II trial led by the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins was initiated to assess this triplet's efficacy but was terminated early due to low patient accrual.
- Brand names
- Lozanoc
- Other names
- SUBA-itraconazole with Cisplatin/Gemcitabine
02
Targets
DNA polymerase (replicative)RNR (Ribonucleotide reductase)SMO (Smoothened)DNAFGF (Fibroblast growth factor 6)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on cisplatin + gemcitabine + itraconazole.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cisplatin + gemcitabine + itraconazole.